| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Prestige Consumer Healthcare Inc.$46.05
+0.59 (+1.3%)
C 50Pipeline Score NOT_PHARMA · Commercial
Market Cap
2.27 B
EPS
3.93
P/E Ratio
12.27 $
Value Trade
28.10 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.09 B
Operating CF
257.63 M
Total Assets
3.49 B
Total Liabilities
1.61 B
Equity
1.89 B
D/E Ratio
12,345
3.47 %
Week
-16.48 %
1 Month
-30.42 %
3 Month
-19.23 %
6 Month
-4.21 %
5 Year
174.29 %
All Time
Cash Data
Cash Position
63.87 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
724.38 K
52 Week Range
42.62 - 87.12
% held by Insiders
1.48 %
% held by Institutions
112.03 %
Enterprise Value
3.26 B
Total Shares
47.31 M
Short %
5.31 %
Float Shares
46.65 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C50
Pipeline Score $1.0B
Pipeline ValueValuation Signal
4
Drugs Scored1.5x
rNPV / MCap Top 77%
Small Cap (rank 209 of 905)
Percentile RankPrestige Consumer Healthcare Inc. carries a moderate pipeline score (50/100), with $3.1B risk-adjusted pipeline value, led by HD204 in Lung Cancer (Phase 3), across $55B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HD204 Small molecule | Lung Cancer | Phase 3 | NCT03390686 | 46% | $2.6B | ACTIVE NOT_RECRUITING | 650 | AVERAGE | B (77) | Dec 1, 2025 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PBH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PBH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PBH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PBH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PBH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PBH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PBHPrestige Consumer Healthcare Inc Completes Acquisition of Breathe Right TARRYTOWN, N.Y.
Prestige Consumer Healthcare Inc. has finalized the acquisition of the Breathe Right brand and other assets from Foundation Consumer Healthcare for approximately $1.045 billion. This acquisition, first announced on March 20, 2026, positions Breathe Right as Prestige's largest brand and marks its expansion into a new category. The deal was financed through available cash and a new Term Loan B, highlighting Prestige's strategic growth in the consumer healthcare market.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026 Diluted EPS of $3.91 and Adjusted
Prestige Consumer Healthcare Inc. reported its fiscal 2026 results, showcasing revenues of $1,088.7 million despite a 4.3% decline from the previous year. The company announced the acquisition of LaCorium Health for approximately $150 million, which is expected to enhance growth in the therapeutic skin care market. Adjusted diluted earnings per share reached $4.38, down from $4.52 a year prior. The outlook for fiscal 2027 suggests organic revenue growth between 1% and 3%, but challenges in the Eye Ear Care category and overall consumer stability remain concerns.
Read more →PBHM A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Safe Harbor Disclosure 2 This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigati
Prestige Brands recently announced the acquisition of Breathe Right, a leading brand in the nasal strips market, for $1.045 billion. This deal is projected to immediately enhance Prestige's revenue, margins, and free cash flow while aligning with its growth strategy. The acquisition is subject to regulatory approvals and includes a financing structure that will involve new debt, initially raising the company's leverage. However, Prestige aims for rapid deleveraging, positioning itself for long-term success in the consumer healthcare sector.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results Revenue of $283.4 million in Q3, ahead of outlook Diluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior ye
Prestige Consumer Healthcare Inc. reported its financial results for Q3 and the first nine months of fiscal 2026, with revenues of $283.4 million, slightly exceeding expectations but down from the previous year. The diluted earnings per share (EPS) was $0.97, lower than last year's $1.22, primarily due to decreased sales in the Eye Ear Care category. The company has repurchased approximately 0.8 million shares during the quarter and successfully completed the acquisition of Pillar5 Pharma. Looking ahead, Prestige has narrowed its fiscal 2026 revenue outlook to about $1.1 billion amid a challenging consumer environment.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results Revenue of $274.1 million in Q2, ahead of outlook Diluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior yea
Prestige Consumer Healthcare Inc. reported its second quarter and first half fiscal 2026 results, revealing revenues of $274.1 million for Q2, which was above expectations but down 3.4% from the previous year. The company's diluted EPS for Q2 was reported at $0.86, down slightly from $1.09 in the same quarter last year. The company remains focused on rebuilding supply chain capacity for its Clear Eyes product, while also updating its earnings per share outlook for fiscal 2026 to the higher end of the previous range. Despite challenges in the Eye Ear Care category due to supply issues, the firm continues to emphasize brand building and shareholder value enhancement.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results Revenue of $249.5 million in Q1 decline driven by limited eye care supply Diluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adju
Prestige Consumer Healthcare Inc. reported its first quarter results for fiscal 2026, revealing a revenue decline to $249.5 million, largely attributed to supply constraints affecting its Clear Eyes product. Although diluted earnings per share (EPS) rose 6% to $0.95, the company's overall performance was impacted by lower shipments and a revised revenue outlook. To address production issues, Prestige announced an acquisition of Pillar5 Pharma, aiming to improve its eye care supply capacity. The adjusted revenue outlook for fiscal 2026 is now between $1,100 and $1,115 million.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025 Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025 Diluted EPS of
Prestige Consumer Healthcare Inc. reported impressive financial results for fiscal year 2025, achieving record revenues of $1,137.8 million and a diluted EPS of $4.29. Q4 revenues reached $296.5 million, reflecting a 7.9% organic growth. While the company is optimistic about fiscal 2026, projecting organic revenue growth of 1-2%, it also anticipates challenges related to inflationary tariffs and supply limitations for certain products. Overall, the results demonstrate steady performance in a diverse market environment.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook Revenue of $290.3 million in Q3, up 2.7% versus prior year Diluted EPS of $1.22 in Q3 increased approximately 1
Prestige Consumer Healthcare Inc. reported record third quarter results, achieving revenues of $290.3 million, which is a 2.7% increase from the previous year. The company's diluted earnings per share also rose by 15% to $1.22. They announced a raise in their full-year earnings outlook, facilitated by strong profitability and cash flow. However, performance was somewhat mitigated by declines in the Cough Cold category and challenges in meeting demand for their Clear Eyes product line.
Read more →PBHPrestige Consumer Healthcare Inc. Expands CFO Christine Sacco's Role to Include Chief Operating Officer Responsibilities TARRYTOWN, N.Y.
Prestige Consumer Healthcare Inc. has announced the expansion of Chief Financial Officer Christine Sacco's role to include Chief Operating Officer responsibilities. This change is effective immediately and is aimed at enhancing the execution of the company's strategic initiatives. Sacco, who has been CFO since 2016, has been instrumental in driving sales and earnings growth. Her extensive experience in both finance and supply chain management positions her well for this dual role.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2025 Results Revenue of $283.8 Million in Q2, Ahead of Outlook Diluted EPS of $1.09 in Q2, Up 2% Versus Prior Year Net Cash Provided by Opera
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported revenues of $283.8 million for the second quarter of fiscal 2025, slightly down from the prior year but ahead of expectations. The company's diluted EPS rose 2% from last year to $1.09, reflecting positive performance driven by international growth, despite challenges from Clear Eyes supply constraints. Prestige reaffirmed its full-year guidance, anticipating revenue and earnings growth in the latter half of the fiscal year, supported by strong cash flow and a focus on long-term brand growth.
Read more →PBHPrestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2025 Results Revenue of $267.1 Million in Q1, Ahead of Expectations EPS of $0.98 and Adjusted EPS of $0.90 in Q1 Cash from Operations of $54.8 Million up 13.
Prestige Consumer Healthcare Inc. reported its first quarter fiscal 2025 results with revenues of $267.1 million, surpassing expectations despite a 4.4% decline from the previous year. Notable growth in cash from operations and debt reduction bolstered its financial position, with a reaffirmed outlook for the full year. The CEO expressed optimism regarding overcoming supply chain challenges and achieving revenue growth. However, the company faced specific declines in certain product categories, affecting overall revenue performance.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024 Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain Constraints Achieved
Prestige Consumer Healthcare Inc. reported its financial results for the fiscal year ending March 31, 2024, detailing revenue of $1,125.4 million, which reflects a slight decline compared to the previous year. The fourth quarter was particularly affected by supply chain issues impacting product availability, which impacted sales performance. Despite these challenges, the company achieved a leverage ratio of 2.8x and announced a new $300 million share repurchase program. Looking forward, Prestige expects ongoing supply chain challenges to affect growth in fiscal 2025 but remains optimistic about overall performance improvements in the latter half of the year.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior Year Diluted EPS of $1.06 in Q3, Up 2.2% Versus Prior Year Reduced Leverage Ratio to 2.9x
Prestige Consumer Healthcare Inc. reported a revenue of $282.7 million for the third quarter of fiscal 2024, showing a 2.6% increase from the previous year. The diluted earnings per share for the quarter rose to $1.06, up 2.2% compared to the same period last year. The company also improved its leverage ratio to 2.9x and raised its full-year earnings outlook to approximately $4.33. Despite several strong performances in product categories, some declines were noted in Women's Health and Cough Cold segments, which the company plans to strategically exit.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Second Quarter Fiscal 2024 Results Revenue of $286.3 Million in Q2, Ahead of Outlook Diluted EPS of $1.07 in Q2, Up Over 5% Versus Prior Year Reduced Leverage Ratio to 3.0x at Qu
Prestige Consumer Healthcare Inc. reported strong financial results for its second quarter of fiscal 2024, with revenues reaching $286.3 million and a diluted EPS of $1.07, an increase of 5.4% year-over-year. The company reduced its leverage ratio to 3.0x through debt reduction, emphasizing its stable financial position. Despite a slight year-over-year revenue decrease and declines in certain categories, the firm is reaffirming its full-year fiscal 2024 outlook, expecting continued growth in sales and earnings driven by a diverse portfolio and strong brand performance. Management expressed confidence in their ability to navigate the macro environment and create long-term shareholder value.
Read more →PBHPrestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2024 Results Revenue of $279.3 Million in Q1, up 0.8% versus Prior Year and up 1.8% excluding Foreign Currency Reduced Leverage Ratio to 3.2x at Quarter End
Prestige Consumer Healthcare Inc. reported first-quarter fiscal 2024 results, revealing revenue of $279.3 million, a 0.8% increase from the prior year. The company reduced its leverage ratio to 3.2x following a $25 million share repurchase program. Despite a slight decline in net income and international OTC revenues, the overall outlook remains positive, with forecasts reaffirmed for growth in sales and earnings. CEO Ron Lombardi emphasized a strong start to the year, driven by robust performance across several product categories.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Record Fiscal Year 2023 Revenue of $285.9 Million in Q4 and $1,127.7 Million in Fiscal 2023 Organic Revenue Grew 8.0% in Q4 and 3.5% in Fiscal 2023 Achieved Leverage Ratio of 3.3
Prestige Consumer Healthcare Inc. reported a record revenue of $1,127.7 million for fiscal year 2023, representing a growth of 3.8% compared to the previous year. The company achieved organic revenue growth of 8.0% in the fourth quarter, while the leverage ratio improved to 3.3x. Despite these successes, the company posted a significant net loss of $240.6 million for Q4 attributed to non-cash impairments and increased working capital. Looking ahead, Prestige expects modest organic revenue growth of 1% to 2% for fiscal 2024, reflecting planned strategic changes.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Third Quarter Results Revenue of $275.5 Million in Q3 fiscal 2023 increased 0.4% versus Prior Year and 1.8% excluding Currency Diluted EPS of $1.04 for Q3 fiscal 2023 increased 5
Prestige Consumer Healthcare Inc. reported its third-quarter fiscal 2023 results, showcasing a revenue increase to $275.5 million, a 0.4% rise from the previous year. Diluted earnings per share rose to $1.04, up 5.1% year-over-year. Despite solid revenue growth, the company experienced a slight decrease in free cash flow due to increased working capital requirements. The positive performance was mainly driven by the International OTC segment and demand within the Cough Cold category, although some segments faced revenue declines.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Second Quarter Results and Reaffirms Outlook for Fiscal 2023 Record Revenue of $289.3 Million in Q2 fiscal 2023 increased 4.7% versus Prior Year and 5.5% excluding Currency Dilut
Prestige Consumer Healthcare Inc. Reports Second Quarter Results and Reaffirms Outlook for Fiscal 2023 Record Revenue of $289.3 Million in Q2 fiscal 2023 increased 4.7% versus Prior Year and 5.5% excluding Currency Diluted EPS of $1.02 for Q2, ahead of expectations Reduced Deb
Read more →PBHF I R S T Q U A R T E R F Y 2 3 R E S U L T S Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as sta
First Quarter FY 2023 Results August 4th, 2022 Exhibit 99.2 F I R S T Q U A R T E R F Y 2 3 R E S U L T S Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as st
Read more →PBHPrestige Consumer Healthcare Inc. Reports Record Results for Fiscal 2022 Company Exceeds Full-Year Earnings Outlook for Revenue, EPS, and Cash Flow Revenue of $266.9 Million in Q4 and $1,086.8 Million for Full-Year Fisca
Prestige Consumer Healthcare Inc. Reports Record Results for Fiscal 2022 Company Exceeds Full-Year Earnings Outlook for Revenue, EPS, and Cash Flow Revenue of $266.9 Million in Q4 and $1,086.8 Million for Full-Year Fiscal 2022, up 12.3% and 15.2% versus Prior Year, respectively
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2022 Third Quarter Results Revenue of $274.5 Million in Q3, up 14.9% versus Prior Year, up 8.8% on an Organic Basis Diluted EPS of $0.99 in Q3, up 22.2% versus Prior Year
Prestige Consumer Healthcare Inc. Reports Fiscal 2022 Third Quarter Results Revenue of $274.5 Million in Q3, up 14.9% versus Prior Year, up 8.8% on an Organic Basis Diluted EPS of $0.99 in Q3, up 22.2% versus Prior Year Non-GAAP Free Cash Flow of $64.1 Million for Third Quarte
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2022 Second Quarter Results Record revenue of $276.2 Million in Q2, up 16.3% versus Prior Year, up 10.5% on an Organic Basis Diluted EPS of $0.89 and Adjusted Diluted EPS
Prestige Consumer Healthcare Inc. Reports Fiscal 2022 Second Quarter Results Record revenue of $276.2 Million in Q2, up 16.3% versus Prior Year, up 10.5% on an Organic Basis Diluted EPS of $0.89 and Adjusted Diluted EPS of $1.02 in Q2, up 30.8% versus Prior Year Net Cash Provi
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2022 First Quarter Results Revenue was $269.2 Million in Q1, up 17.3% versus Prior Year Record Diluted EPS of $1.14 in Q1, up 32.5% versus Prior Year Net Cash Provided by
Prestige Consumer Healthcare Inc. Reports Fiscal 2022 First Quarter Results Revenue was $269.2 Million in Q1, up 17.3% versus Prior Year Record Diluted EPS of $1.14 in Q1, up 32.5% versus Prior Year Net Cash Provided by Operating Activities of $69.3 million and Free Cash Flow
Read more →PBHPrestige Consumer Healthcare Completes Acquisition of TheraTears, Announces First Quarter Fiscal 2022 Earnings Results Date TARRYTOWN, N.Y.
Consumer Healthcare Completes Acquisition of TheraTears, Announces First Quarter Fiscal 2022 Earnings Results Date TARRYTOWN, N.Y., July 01, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) ("Prestige" or the "Company") today announced that it has complete
Read more →PBHPrestige Announces Agreement to Expand Eye Care Offering with Acquisition of TheraTears - Acquisition adds TheraTears brand to Company's leading eye care portfolio - Acquisition expected to add approximately $60 and $20
Prestige Announces Agreement to Expand Eye Care Offering with Acquisition of TheraTears TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 27, 2021-- Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE:PBH) today announced that it has entered into a definitive agreement
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2021 Fourth Quarter and Record Full-Year Results Company Exceeds Full Year 2021 Guidance for Revenue, Adjusted EPS and Free Cash Flow Revenue was $237.8 Million in Q4 and
Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Fourth Quarter and Record Full-Year Results Company Exceeds Full Year 2021 Guidance for Revenue, Adjusted EPS and Free Cash Flow Revenue was $237.8 Million in Q4 and $943.4 in Full-Year Fiscal 2021 Record Diluted EPS of $3.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2021 Third Quarter Results Revenue was $238.8 Million in Third Quarter Fiscal 2021 Diluted EPS of $0.81 in Third Quarter Fiscal 2021 Net Cash Provided by Operating Activit
Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Third Quarter Results Revenue was $238.8 Million in Third Quarter Fiscal 2021 Diluted EPS of $0.81 in Third Quarter Fiscal 2021 Net Cash Provided by Operating Activities for First Nine Months of Fiscal 2021 Increased 10% to
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2021 Second Quarter Results Revenue was $237.4 Million in Second Quarter Fiscal 2021, Approximately Flat to Prior Year Diluted EPS of $0.88 in Second Quarter Fiscal 2021 N
Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Second Quarter Results Revenue was $237.4 Million in Second Quarter Fiscal 2021, Approximately Flat to Prior Year Diluted EPS of $0.88 in Second Quarter Fiscal 2021 Non-GAAP Adjusted Diluted EPS of $0.78 up 15% from Prior Ye
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2021 First Quarter Results Revenue was $229.4 Million in First Quarter Fiscal 2021, Down 0.6% from Prior Year Q1 Excluding Unfavorable Foreign Currency Diluted EPS of $0.8
Prestige Consumer Healthcare Inc. Reports Fiscal 2021 First Quarter Results Revenue was $229.4 Million in First Quarter Fiscal 2021, Down 0.6% from Prior Year Q1 Excluding Unfavorable Foreign Currency Diluted EPS of $0.86 in First Quarter Fiscal 2021, up 32% from Prior Year Q1
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2020 Fourth Quarter and Full-Year Results Revenue was $251.2 Million in Q4 and $963.0 Million in Full-Year Fiscal 2020 Organic Revenue Grew 4.6% in Q4 and 1.3% in Fiscal 2
Prestige Consumer Healthcare Inc. Reports Fiscal 2020 Fourth Quarter and Full-Year Results Revenue was $251.2 Million in Q4 and $963.0 Million in Full-Year Fiscal 2020 Organic Revenue Grew 4.6% in Q4 and 1.3% in Fiscal 2020 Generated Cash from Operations of $217.1 Million and
Read more →PBHPrestige Consumer Healthcare Inc. Announces New $25 Million Share Repurchase Program, Participation in the Raymond James Institutional Investors Conference TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)
Prestige Consumer Healthcare Inc. Announces New $25 Million Share Repurchase Program, Participation in the Raymond James Institutional Investors Conference TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-March 2, 2020-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that the C
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2020 Third Quarter and Year-to-Date Results Revenue $241.6 Million in Q3 Fiscal 2020 Organic Revenue up 0.5% versus Prior Year Q3 GAAP Diluted EPS of $0.75 in Q3 Fiscal 20
Prestige Consumer Healthcare Inc. Reports Fiscal 2020 Third Quarter and Year-to-Date Results Revenue $241.6 Million in Q3 Fiscal 2020 Organic Revenue up 0.5% versus Prior Year Q3 GAAP Diluted EPS of $0.75 in Q3 Fiscal 2020 Adjusted EPS of $0.81, Up 11% Versus Prior Year Q3 Yea
Read more →PBHICR Conference January 13 th , 2020 ICR Conference 2020 2 Safe Harbor Disclosure This presentation contains certain "forward - looking" statements within the meaning of the Private Securities Litigation Reform A ct of 19
ICR Conference January 13 th , 2020 ICR Conference 2020 2 Safe Harbor Disclosure This presentation contains certain "forward - looking" statements within the meaning of the Private Securities Litigation Reform A ct of 1995, such as statements regarding the Company's expected fin
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2020 Second Quarter and Year-to-Date Results Revenue $238.1 Million in Q2 Fiscal 2020; Organic Revenue Flat GAAP Diluted EPS of $0.65 in Q2 Fiscal 2020; Adjusted EPS of $0
Prestige Consumer Healthcare Inc. Reports Fiscal 2020 Second Quarter and Year-to-Date Results TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-October 31, 2019-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and year-to-date fiscal 2020 en
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2020 First Quarter Results Revenue $232.2 Million in Q1 Fiscal 2020; Organic Revenue Flat as Expected EPS of $0.65 in Q1 Fiscal 2020 Cash Flow From Operations of $52.8 Mil
Prestige Consumer Healthcare Inc. Reports Fiscal 2020 First Quarter Results TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-August 1, 2019-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2020 ended June 30, 2019. "Our first quarter
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2019 Fourth Quarter and Full-Year Results Revenue was $241.0 Million in Q4 and $975.8 Million in Full-Year Fiscal 2019 Organic Revenue Grew 3.2% in Q4 and 0.1% in Fiscal 2
Prestige Consumer Healthcare Inc. Reports Fiscal 2019 Fourth Quarter and Full-Year Results TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 9, 2019-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and twelve months ended March 31, 2019.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2019 Third Quarter Results Revenue was $241.4 Million in Q3 Fiscal 2019 as Previously Announced GAAP Diluted EPS of $0.73 in Q3 Reduced Debt by $55 Million in Q3 and $155
Prestige Consumer Healthcare Inc. Reports Fiscal 2019 Third Quarter Results TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-February 7, 2019-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2018. "In Q3 o
Read more →PBHPrestige Consumer Healthcare Inc. Updates Third Quarter and Fiscal 2019 Guidance; Announces Participation in the 21 st Annual ICR Conference TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)
Prestige Consumer Healthcare Inc. Updates Third Quarter and Fiscal 2019 Guidance; Announces Participation in the 21st Annual ICR Conference TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)--Jan. 14, 2019-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today updated its guidance for the third
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2019 Second Quarter Results Revenue was $239.4 Million in Q2 Fiscal 2019; Organic Revenue Growth of 1.6% Excluding Household Cleaning Divestiture GAAP Diluted EPS Increase
Prestige Consumer Healthcare Inc. Reports Fiscal 2019 Second Quarter Results TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 1, 2018-- Prestige Consumer Healthcare Inc. (NYSE:PBH), formerly Prestige Brands Holdings, Inc., today reported financial results for its second quarter and si
Read more →PBHPrestige Brands Holdings, Inc.
Prestige Brands Holdings, Inc. Reports Fiscal 2019 First Quarter Results; Announces Name Change to Prestige Consumer Healthcare, Inc. TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)--August 2, 2018-- Prestige Brands Holdings, Inc. (NYSE:PBH) today reported financial results for its first quar
Read more →PBHPrestige Brands Holdings, Inc. Announces Strategic Sale of Household Cleaning Business Transaction Focuses the Company on its Portfolio of Leading Consumer Healthcare Brands Proceeds Will be Used to Further Reduce Debt C
Prestige Brands Holdings, Inc. Announces Strategic Sale of Household Cleaning Business TARRYTOWN, N.Y., July 2, 2018 (GLOBE NEWSWIRE) -- Prestige Brands Holdings, Inc. (NYSE:PBH) (the "Company" or "Prestige") announced today that it has signed and closed on an agreement for t
Read more →PBHWilliam Blair Growth Stock Conference 2 Safe Harbor Disclosure This presentation contains certain "forward - looking" statements within the meaning of the Private Securities Litigation Reform A ct of 1995, such as statem
William Blair Growth Stock Conference June 13, 2018 Exhibit 99.1 William Blair Growth Stock Conference 2 Safe Harbor Disclosure This presentation contains certain "forward - looking" statements within the meaning of the Private Securities Litigation Reform A ct of 1995, such as
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal 2018 Fourth Quarter and Full Year Results; Provides Fiscal 2019 Outlook Reported Revenue Increased 6.4% to $256.0 Million and 18.0% to $1,041.2 Million in Q4 and Fiscal 2018,
Prestige Brands Holdings, Inc. Reports Fiscal 2018 Fourth Quarter and Full Year Results; Provides Fiscal 2019 Outlook TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 10, 2018-- Prestige Brands Holdings, Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal yea
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal 2018 Third Quarter Results Revenue Increased 24.8% to $270.6 Million in Q3 Fiscal 2018; Year to Date Revenues up 22.4% to $785.2 Million GAAP Diluted EPS, Including Gain from
Prestige Brands Holdings, Inc. Reports Fiscal 2018 Third Quarter Results TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-February 1, 2017-- Prestige Brands Holdings, Inc. (NYSE:PBH) today reported financial results for its third quarter and nine-months ended December 31, 2017. "We were pleas
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal 2018 Second Quarter Results; Reaffirms Fiscal 2018 Outlook Revenue Increased 20.0% to $258.0 Million in Q2 Fiscal 2018; First Half Revenues up 21.2% to $514.6 Million Q2 Cons
Prestige Brands Holdings, Inc. Reports Fiscal 2018 Second Quarter Results; Reaffirms Fiscal 2018 Outlook TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 2, 2017-- Prestige Brands Holdings, Inc. (NYSE:PBH) today reported financial results for its second quarter ended September 30, 201
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal 2018 First Quarter Results; Reaffirms Fiscal 2018 Outlook Revenue Increased 22.4% to $256.6 Million in Q1 Fiscal 2018; Revenue Growth of 3.0% Pro-forma for Fleet Adjusted EPS
Prestige Brands Holdings, Inc. Reports Fiscal 2018 First Quarter Results; Reaffirms Fiscal 2018 Outlook TARRYTOWN, N.Y.--(BUSINESS WIRE)--August 3, 2017-- Prestige Brands Holdings, Inc. (NYSE:PBH) today reported financial results for its first quarter ended June 30, 2017. "Our
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal 2017 Fourth Quarter and Full Year Results; Provides Fiscal 2018 Outlook - Reported revenue increased 15.8% to $240.7 million and 9.4% to $882.1 million in Q4 and fiscal 2017,
Prestige Brands Holdings, Inc. Reports Fiscal 2017 Fourth Quarter and Full Year Results; Provides Fiscal 2018 Outlook TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 11, 2017-- Prestige Brands Holdings, Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal yea
Read more →PBHPrestige Brands Holdings, Inc. Reports Third Quarter Fiscal 2017 Results Q3 Revenues Up 8.3% to $216.8 Million; First Nine Month Revenues Up 7.2% Q3 GAAP Diluted EPS Increased Approximately 11% to $0.59; Non-GAAP Adjuste
Prestige Brands Holdings, Inc. Reports Third Quarter Fiscal 2017 Results TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 2, 2017-- Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the third quarter of fiscal year 2017, which ended December 31, 2016. "We are very ple
Read more →PBHTransaction Overview On
Transaction Overview On December 21, 2016, Prestige Brands Holdings, Inc. (NYSE: PBH) ("Prestige," or the "Company") agreed to acquire C.B. Fleet Company, Inc. ("Fleet") for a purchase price of $825mm Fleet is a best - in - class consumer health company that manufactures and mark
Read more →PBHto our Form 8 - K dated
ICR Conference 2017 January 10 th and 11 th Ron Lombardi, President & CEO | Christine Sacco, CFO NYSE: PBH Exhibit 99.1 2 This presentation contains certain "forward - looking" statements within the meaning of the Private Securities Litigation Reform A ct of 1995, such as statem
Read more →PBHPrestige Brands Announces Agreement to Acquire C.B. Fleet Company Adds Leading Brand to Women's Health Portfolio Acquisition Positions the Company for Pro Forma Revenue of Approximately $1.0 billion in Fiscal 2018 Moves
Prestige Brands Announces Agreement to Acquire C.B. Fleet Company Adds Leading Brand to Women's Health Acquisition Positions the Company for Pro Forma Revenue of Approximately $1.0 billion in Fiscal 2018 Moves Prestige Towards its Targeted Mix of "Invest-for-Growth" Brands
Read more →PBHPrestige Brands Holdings, Inc. completes sale of DermoPlast to Moberg Pharma AB; Licenses Massengill TARRYTOWN, N.Y.--(BUSINESS WIRE)
Brands Holdings, Inc. completes sale of DermoPlast to Moberg Pharma AB; Licenses Massengill TARRYTOWN, N.Y.--(BUSINESS WIRE)-- December 7, 2016-- Prestige Brands Holdings, Inc. (NYSE:PBH) (the "Company" or "Prestige") announced today that it has entered into an agreement for t
Read more →PBHPrestige Brands Holdings, Inc. Reports Second Quarter Fiscal 2017 Results Q2 Revenues Up 4.4% to $215.1 Million; First Half Year Revenues Up 6.6% Q2 EPS of $0.60; Non-GAAP Adjusted EPS Increased 5.0% to $0.63 Q2 Net Cash
Prestige Brands Holdings, Inc. Reports Second Quarter Fiscal 2017 Results Tarrytown, NY-(Business Wire)-November 3, 2016--Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the second quarter of fiscal year 2017, which ended September 30, 2016. "We are please
Read more →PBHFOR RELEASE ON MONDAY, September 12 TH Prestige Brands Holdings, Inc. Appoints Christine Sacco as New Chief Financial Officer Tarrytown, NY
FOR RELEASE ON MONDAY, September 12TH Prestige Brands Holdings, Inc. Appoints Christine Sacco as New Chief Financial Officer Tarrytown, NY-September 12, 2016-Prestige Brands Holdings, Inc. (NYSE-PBH), a leading marketer of over-the-counter healthcare products, today announced
Read more →PBHPrestige Brands Holdings, Inc. Reports First Quarter Fiscal 2017 Revenues Up 9.1% to $209.6 Million Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports First Quarter Fiscal 2017 Revenues Up 9.1% to $209.6 Million Tarrytown, NY-(Business Wire)--August 4, 2016--Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the first quarter of fiscal year 2017, which ended June 30, 2
Read more →PBHPrestige Brands Holdings, Inc. Completes Divestiture of Three Brands to Moberg Pharma AB Tarrytown, NY
Prestige Brands Holdings, Inc. Completes Divestiture of Three Brands to Moberg Pharma AB Tarrytown, NY, July 7, 2016-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced that it has closed the previously announced divestiture of three of its non-core over-the-counter hea
Read more →PBHPrestige Brands Holdings, Inc. To Sell Three Brands To Moberg Pharma AB Prestige To Release First Quarter Fiscal 2017 Results on August 4 th Tarrytown, NY
Prestige Brands Holdings, Inc. To Sell Three Brands To Moberg Prestige To Release First Quarter Fiscal 2017 Results on Tarrytown, NY, June 30, 2016-Prestige Brands Holdings, Inc. (NYSE-PBH) (the "Company" or "Prestige") announced today that it has entered into an agreement for
Read more →PBHSafe Harbor Disclosure This presentation contains certain forward-looRing statements within the meaning of the Priuate Securities Litigation Reform Act of 1995, such as statements regarding the Company s expected financi
l?r estigeBrands MONISTAT' FESS) Jiydralyte Cl r eyes. CQlJGJ.f & co (1-;n&- # .fr-Mi .-. () LLJDE N'S. U1'1 t 1tf f.0,ts beanh GOf!ff'//!ne Dramamme Exhibit 99.1 Safe Harbor Disclosure This presentation contains certain "forward-looRing" statements within the meaning of the Pri
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal 2016 Fourth Quarter and Full Year Results Company Exceeds Fourth Quarter and Full Year Outlook Fourth Quarter Revenues Up 9.4%: Full Year Revenues Up 12.8% Adjusted Free Cash
Prestige Brands Holdings, Inc. Reports Fiscal 2016 Fourth Quarter and Full Year Results Company Exceeds Fourth Quarter and Full Year Outlook Fourth Quarter Revenues Up 9.4%: Full Year Revenues Up 12.8% Adjusted Free Cash Flow Increased 12.0% to $183.4 Million in FY2016 Tarryt
Read more →PBHPrestige Brands Holdings, Inc. Announces Pricing of $350 Million Senior Notes Tarrytown, NY
Prestige Brands Holdings, Inc. Announces Pricing of $350 Million Senior Notes Tarrytown, NY, February 16, 2016 - Prestige Brands Holdings, Inc. (NYSE: PBH) (the "Company") announced today that its wholly-owned subsidiary, Prestige Brands, Inc. ("Prestige Brands"), has priced an
Read more →PBHDean Siegal (914) 524-6819 2
Prestige Brands Holdings, Inc. Announces Offering of $350 Million Senior Notes Tarrytown, NY, February 16, 2016 - Prestige Brands Holdings, Inc. (NYSE: PBH) (the "Company") announced today that its wholly-owned subsidiary, Prestige Brands, Inc. ("Prestige Brands"), intends to of
Read more →PBHPrestige Brands Holdings, Inc. Completes Acquisition of DenTek Holdings, Inc. Tarrytown, NY (Business Wire)
Prestige Brands Holdings, Inc. Completes Acquisition of DenTek Holdings, Inc. Tarrytown, NY (Business Wire), February 8, 2016 - Prestige Brands Holdings, Inc. (NYSE-PBH) ("Prestige") today announced that it has closed the previously announced acquisition of DenTek Holdings, Inc
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal 2016 Third Quarter and Year-to-Date Results Closing of DenTek Acquisition Expected in Early February with FTC Review Now Completed Company Reiterates Fiscal 2016 Revenue, Adj
Prestige Brands Holdings, Inc. Reports Fiscal 2016 Third Quarter and Year-to-Date Results Closing of DenTek Acquisition Expected in Early February with FTC Review Now Completed Company Reiterates Fiscal 2016 Revenue, Adjusted Free Cash Flow and Adjusted EPS Guidance Tarrytown,
Read more →PBHPrestige Brands Announces Agreement to Acquire DenTek Holdings, Inc. Acquisition Will Add Scale Brand and Expands Oral Care Platform Conference Call Scheduled Today at 10:30am Tarrytown, NY
Prestige Brands Announces Agreement to Acquire DenTek Holdings, Acquisition Will Add Scale Brand and Expands Oral Care Platform Conference Call Scheduled Today at 10:30am Tarrytown, NY-November 23, 2015-Prestige Brands Holdings, Inc. (NYSE-PBH) ("Prestige") today announced th
Read more →PBHPrestige Brands Holdings, Inc. Reports Record Second Quarter Fiscal 2016 Revenues Up 13.7% to $206.1 Million Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Record Second Quarter Fiscal 2016 Revenues Up 13.7% to Tarrytown, NY-(Business Wire)-November 5, 2015--Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the second quarter and first six months of fiscal year 2016, which
Read more →PBHAbout Prestige Brands Holdings, Inc. The Company markets and distributes brand name over-the-counter healthcare and household cleaning products throughout the U.S., Canada, and Australia and in certain other internationa
David Marberger Appointed Chief Financial Officer of Prestige Brands Holdings, Inc. Tarrytown, NY, October 28, 2015-Prestige Brands Holdings, Inc. (NYSE-PBH), a leading marketer of over-the-counter healthcare products, today announced the appointment of David Marberger to the
Read more →PBHPrestige Brands Holdings, Inc. Reports Record First Quarter Fiscal 2016 Revenues Up 31.9% to $192.1 Million & Free Cash Flow Up 46.5% to $42.7 Million Outlook Reaffirmed for Fiscal Year 2016 Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Record First Quarter Fiscal 2016 Revenues Up 31.9% to $192.1 Million & Free Cash Flow Up 46.5% to $42.7 Million Outlook Reaffirmed for Fiscal Year 2016 Tarrytown, NY-(Business Wire)--August 6, 2015--Prestige Brands Holdings, Inc. (NYSE-PBH
Read more →PBHPrestige Brands Holdings, Inc. Reports Record Fiscal 2015 Fourth Quarter and Full Year Results Fourth Quarter Revenues Up 32.9%: Full Year Earnings Up 19.6% Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Record Fiscal 2015 Fourth Quarter and Full Year Results Fourth Quarter Revenues Up 32.9%: Full Year Earnings Up 19.6% Tarrytown, NY-(Business Wire)-May 14, 2015--Prestige Brands Holdings, Inc. (NYSE: PBH) today reported strong financial re
Read more →PBHPrestige Brands Announces Ron Lombardi to Succeed Matt Mannelly as President and Chief Executive Officer -Matthew Mannelly Plans to Retire in June 2015- -Board of Directors Select Ron Lombardi as President and CEO- -Comp
Prestige Brands Announces Ron Lombardi to Succeed Matt Mannelly as President and Chief Executive Officer -Matthew Mannelly Plans to Retire in -Board of Directors Select Ron Lombardi as President and CEO- -Company Expects to Achieve Upper End of Previously Announced Fourth Fi
Read more →PBHto our Form 8-K filed with the SEC on
Presentation to Clients of Raymond James February 2015 Exhibit 99.1 2 This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's product introductions, geograp
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal Third Quarter 2015 and Year-to-Date Results Record Third Quarter Revenues Up 36.4% Achieved Third Quarter Organic Growth of 2.1% Outlook for Full Fiscal Year 2015 Updated Tar
Prestige Brands Holdings, Inc. Reports Fiscal Third Quarter 2015 and Year-to-Date Results Record Third Quarter Revenues Up 36.4% Achieved Third Quarter Organic Growth of 2.1% Outlook for Full Fiscal Year 2015 Updated Tarrytown, NY-(Business Wire)-February 5, 2015--Prestige Br
Read more →PBHNon-GAAP Financial Measures We define Non-GAAP Adjusted EBITDA as earnings before (income) loss from discontinued operations, loss (gain) on sale of discontinued operations, interest expense (income), income taxes, depre
Non-GAAP Financial Measures We define Non-GAAP Adjusted EBITDA as earnings before (income) loss from discontinued operations, loss (gain) on sale of discontinued operations, interest expense (income), income taxes, depreciation and amortization, certain other legal and professio
Read more →PBHaccompanying Form 8-K filed
M O R G A N S T A N L E Y G L O B A L C O N S U M E R C O N F E R E N C E 1 Morgan Stanley Global Consumer Conference Matt Mannelly, CEO & President Ron Lombardi, CFO November 18, 2014 Exhibit 99.1 M O R G A N S T A N L E Y G L O B A L C O N S U M E R C O N F E R E N C E 2 This
Read more →PBHPrestige Brands Holdings, Inc. Reports Second Quarter Revenue Up 8.6%; Integration of Insight Pharmaceuticals Acquisition On Track Outlook for Full Fiscal Year '15 Reconfirmed Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Second Quarter Revenue Up 8.6%; Integration of Insight Pharmaceuticals Acquisition On Track Outlook for Full Fiscal Year '15 Reconfirmed Tarrytown, NY-(Business Wire)-November 6, 2014--Prestige Brands Holdings, Inc. (NYSE-PBH) today announ
Read more →PBHPrestige Brands Holdings, Inc. Completes Purchase of Insight Pharmaceuticals Corporation Tarrytown, NY, (Business Wire)
Prestige Brands Holdings, Inc. Completes Purchase of Insight Pharmaceuticals Corporation Tarrytown, NY, (Business Wire), September 3, 2014--Prestige Brands Holdings, Inc. (NYSE:PBH) ("Prestige") today announced that it has closed the previously announced acquisition of Insigh
Read more →PBHPrestige Brands Holdings, Inc. Reports First Quarter Fiscal 2015 Revenues of $145.7 Million Up 2.2%: Outlook Reaffirmed for Fiscal Year 2015 Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports First Quarter Fiscal 2015 Revenues of $145.7 Million Up 2.2%: Outlook Reaffirmed for Fiscal Year 2015 Tarrytown, NY-(Business Wire)-August 7, 2014-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the first quarter of fi
Read more →PBHPrestige Brands Holdings, Inc. Reports Fourth Quarter & Fiscal 2014 Results & Provides Outlook for Fiscal 2015 Industry-Leading Free Cash Flow Projected To Strengthen in F'15 from Recently Announced Acquisitions & New Co
Prestige Brands Holdings, Inc. Reports Fourth Quarter & Fiscal 2014 Results & Provides Outlook for Fiscal 2015 Industry-Leading Free Cash Flow Projected To Strengthen in F'15 from Recently Announced Acquisitions & New Consumer Platforms TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 15,
Read more →PBHPrestige Brands Holdings, Inc. Completes Purchase of Hydralyte for Its Australian Subsidiary Tarrytown, NY
Prestige Brands Holdings, Inc. Completes Purchase of Hydralyte for Its Australian Subsidiary Tarrytown, NY, May 1, 2014-Prestige Brands Holdings, Inc. (NYSE-PBH) ("Prestige") today announced that it has closed the previously announced acquisition of Hydralyte from the Hydration
Read more →PBHPrestige Brands Announces Agreement to Acquire Insight Pharmaceuticals Adds New Platform in Feminine Care & Strengthens the Prestige Brands Portfolio Tarrytown, NY
Prestige Brands Announces Agreement to Acquire Insight Pharmaceuticals Adds New Platform in Feminine Care & Strengthens the Prestige Brands Portfolio Tarrytown, NY, April 25, 2014-Prestige Brands Holdings, Inc.("Prestige" or the "Company") (NYSE-PBH) today announced that it h
Read more →PBHFor Release 7AM ET; Tuesday
For Release 7AM ET; Tuesday, April 15, 2014 Prestige Brands Announces Agreement to Acquire Hydralyte, the Leading OTC Oral Rehydration Product in Australia Acquisition Will Double Australian Subsidiary's Revenues Tarrytown, NY-April 15, 2014-Prestige Brands Holdings, Inc. (NYS
Read more →PBHPrestige Brands Holdings, Inc. Reports Fiscal Third Quarter & Nine Month Results; Results Impacted by Retailer Inventory Reductions, Return of Competing Products & Soft Cough/Cold Season Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Fiscal Third Quarter & Nine Month Results; Results Impacted by Retailer Inventory Reductions, Return of Competing Products & Soft Cough/Cold Season Tarrytown, NY-(Business Wire)-February 6, 2014-Prestige Brands Holdings, Inc. (NYSE-PBH) to
Read more →PBHPrestige Brands Holdings, Inc. Announces Initial Results of Tender Offer and Consent Solicitation of 8.25% Senior Notes due 2018 Tarrytown, NY
Prestige Brands Holdings, Inc. Announces Initial Results of Tender Offer and Consent Solicitation of 8.25% Senior Notes due 2018 Tarrytown, NY, December 17, 2013- Prestige Brands Holdings, Inc. (NYSE: PBH) (the "Company") announced today that its wholly owned subsidiary, Prest
Read more →PBHPrestige Brands Holdings , Inc. Announces Offering of $400 Million Senior Note s Tarrytown, NY
Prestige Brands Holdings, Inc. Announces Offering of $400 Million Senior Notes Tarrytown, NY, December 3, 2013- Prestige Brands Holdings, Inc. (NYSE: PBH) (the "Company") announced today that its wholly-owned subsidiary, Prestige Brands, Inc. ("Prestige Brands"), intends to o
Read more →PBHPrestige Brands Holdings, Inc. Reports Record Second Quarter Revenue of $168.4 Million; Record Operating Income of $53.8 Million Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Record Second Quarter Revenue of $168.4 Million; Record Operating Income of $53.8 Million Tarrytown, NY-(Business Wire)-November 7, 2013-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the second quarter and first six
Read more →PBHPrestige Brands Holdings, Inc. Reports Record First Quarter EPS of $0.40 vs. $0.29, Up 37.9% Revenue Estimate Updated for Acquisition of Care Pharmaceuticals Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Record First Quarter EPS of $0.40 vs. $0.29, Up 37.9% Revenue Estimate Updated for Acquisition of Care Pharmaceuticals Tarrytown, NY-(Business Wire)-August 1, 2013-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the f
Read more →PBHPrestige Brands Holdings, Inc. Reports Record Fourth Quarter Revenues Up 15.3% and EPS of $0.37 Fiscal 13 Revenues Increase 41%; Reported EPS Up 74% to $1.27 Investor Day Slated for May 22nd Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports Record Fourth Quarter Revenues Up 15.3% Fiscal 13 Revenues Increase 41%; Reported EPS Up 74% to $1.27 Investor Day Slated for May 22nd Tarrytown, NY-(Business Wire)-May 16, 2013-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced re
Read more →PBHPrestige Brands Holdings, Inc. Reports 50.8% Revenue Increase & Record Earnings for Third Quarter of Fiscal 2013; Year-To-Date Revenues Increase 52.8% Full Year F'13 EPS Guidance Increased Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports 50.8% Revenue Increase & Record Earnings for Third Quarter of Fiscal 2013; Year-To-Date Revenues Increase 52.8% Full Year F'13 EPS Guidance Increased Tarrytown, NY-(Business Wire) February 7, 2013-Prestige Brands Holdings, Inc. today annou
Read more →PBHPrestige Brands Holdings, Inc. Reports 53.4% Revenue Increase & Record Earnings for Second Quarter of Fiscal 2013 Full Year EPS Guidance Increased; Divestiture of Phazyme Announced Tarrytown, NY-(Business Wire)
Prestige Brands Holdings, Inc. Reports 53.4% Revenue Increase & Record Earnings for Second Quarter of Fiscal 2013 Full Year EPS Guidance Increased; Divestiture of Phazyme Announced Tarrytown, NY-(Business Wire) November 1, 2012-Prestige Brands Holdings, Inc. today announced res
Read more →PBHPrestige Brands Holdings, Inc. Reports Record Revenue Increase of 54% for First Quarter Fiscal 2013 Irvington, NY
Prestige Brands Holdings, Inc. Reports Record Revenue Increase of 54% for First Quarter Fiscal 2013 Irvington, NY, August 7, 2012-- Prestige Brands Holdings, Inc. today announced results for the first fiscal quarter ended June 30, 2012, including record first quarter revenues of
Read more →PBHPrestige Brands Holdings, Inc. Completes Purchase of Debrox and Gly-Oxide from GSK Finalizing 17 Brand Transaction IRVINGTON, NY,--(BUSINESS WIRE)
Prestige Brands Holdings, Inc. Completes Purchase of Debrox and Gly-Oxide from GSK Finalizing 17 Brand Transaction IRVINGTON, NY,--(BUSINESS WIRE)--April 2, 2012--Prestige Brands Holdings, Inc. (NYSE-PBH) today announced that it has completed the purchase of the two remaining
Read more →PBHPrestige Brands Expects To Report Revenue Growth of Approximately 38% And Adjusted EPS of Approximately $0.23 in Current Quarter Expects Adjusted EPS of $1.22 to $1.32 in Fiscal 2013 IRVINGTON, N.Y.
Prestige Brands Expects To Report Revenue Growth of Approximately 38% And Adjusted EPS of Approximately $0.23 in Expects Adjusted EPS of $1.22 to $1.32 IRVINGTON, N.Y. -- March 22, 2012-- Prestige Brands Holdings, Inc. (NYSE - PBH) today provided estimated financial results
Read more →PBHPrestige Brands Comments on Genomma Lab's Intention to Nominate Directors IRVINGTON, N.Y.
Prestige Brands Comments on Genomma Lab's Intention to Nominate Directors IRVINGTON, N.Y.-- March 15, 2012-- Prestige Brands Holdings, Inc. (NYSE - PBH) today issued the following statement in response to receipt of notice that Genomma Lab Internacional, S.A.B. de C.V. is see
Read more →PBHPRESTIGE BRANDS REJECTS UNSOLICITED PROPOSAL FROM GENOMMA LAB Irvington, NY
PRESTIGE BRANDS REJECTS UNSOLICITED PROPOSAL FROM GENOMMA LAB Irvington, NY, March 12, 2012 -- Prestige Brands Holdings, Inc. (NYSE: PBH) announced today that its Board of Directors has unanimously rejected Genomma Lab Internacional, S.A.B. de C.V.'s unsolicited, highly conditio
Read more →PBHPrestige Brands Holdings, Inc. Adopts Stockholder Rights Plan Irvington, NY
Prestige Brands Holdings, Inc. Adopts Stockholder Rights Plan Irvington, NY- February 27, 2012--Prestige Brands Holdings, Inc. (NYSE: PBH) (the "Company") today announced that its Board of Directors has unanimously approved the adoption of a stockholder rights plan. The Board ad
Read more →PBHPrestige Brands Holdings, Inc. Reacts to Unsolicited Non-Binding Highly-Conditional Letter from Genomma Lab Irvington, NY
Prestige Brands Holdings, Inc. Reacts to Unsolicited Non-Binding Highly-Conditional Letter from Genomma Lab Irvington, NY- February 21, 2012--Prestige Brands Holdings, Inc. (NYSE - PBH) today confirmed that it is in receipt of a non-binding letter from Genomma Lab Internacional,
Read more →PBHFor Release on
For Release on January 31, 2012, 9:30 PM ET Prestige Brands Holdings, Inc. Completes Purchase of 15 Brands Irvington, NY, January 31, 2012-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced that it has completed its previously announced purchase of fifteen of the sevent
Read more →PBHPrestige Brands Holdings , Inc. Announces Pricing of $250 Million Senior Note s Due 2020 Irvington, NY
Prestige Brands Holdings, Inc. Announces Pricing of $250 Million Senior Notes Due 2020 Irvington, NY, January 24, 2012- Prestige Brands Holdings, Inc. (NYSE: PBH) (the "Company") announced today that its wholly-owned subsidiary, Prestige Brands Inc. ("Prestige Brands"), has p
Read more →PBHPrestige Brands, Inc. Announces Offering of $290 Million Senior Notes Irvington, NY
Prestige Brands, Inc. Announces Offering of $290 Million Senior Notes January 18, 2012 Prestige Brands Holdings, Inc. (NYSE: PBH) (the Company ) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. ( Prestige Brands ), intends to offer, subject to market and o
Read more →PBHPrestige Brands Holdings, Inc. Signs Definitive Agreements With GSK To Acquire 17 Consumer OTC Healthcare Brands in North America Transactions Will Be The Largest in the Company's History Irvington, NY
Prestige Brands Holdings, Inc. Signs Definitive Agreements With GSK To Acquire 17 Consumer OTC Healthcare Brands in North America Transactions Will Be The Largest in the Company's History Irvington, NY, December 20, 2011-- Prestige Brands Holdings, Inc. (NYSE-PBH) today announc
Read more →PBHPrestige Brands Holdings, Inc. Reports Third Quarter & Nine Months Fiscal 2011 Results For the Quarter, Prestige Reports Strong Revenue Growth, Driven by Core OTC Growth and Blacksmith Brands Acquisition IRV
Brands Holdings, Inc. Reports Third Quarter & Nine Months Fiscal 2011 the Quarter, Prestige Reports Strong Revenue Growth, Driven by Core OTC Growth and Blacksmith Brands Acquisition N.Y., Feb 9, 2011 (BUSINESS WIRE) -- Brands Holdings, Inc. (NYSE:PBH) today announced results
Read more →PBHPrestige Brands Holdings, Inc. Reports Second Quarter & Six Months Fiscal 2011 Results For the Quarter, EPS of $0.23 vs. $0.18; Income from Continuing Operations Up 28%; Completes Acquisition of Blacksmith Brands on Nove
Prestige Brands Holdings, Inc. Reports Second Quarter & Six Months Fiscal 2011 Results For the Quarter, EPS of $0.23 vs. $0.18; Income from Continuing Operations Up 28%; Completes Acquisition of Blacksmith Brands on November 1 Irvington, NY-November 4, 2010-Prestige Brands Hold
Read more →PBHPRESTIGE BRANDS, INC. ANNOUNCES $100
PRESTIGE BRANDS, INC. ANNOUNCES $100 MILLION SENIOR NOTE OFFERING N.Y., Oct 22, 2010 (BUSINESS WIRE) -- Prestige Brands Holdings, Inc. (NYSE: PBH) (the "Company") announced today that its wholly-owned subsidiary Prestige Brands, Inc. ("Prestige Brands") is making a private pla
Read more →PBHPrestige Announces Agreement to Acquire Blacksmith Brands IRVINGTON, N.Y.
Announces Agreement to Acquire Blacksmith Brands N.Y., September 20, 2010 - Prestige Brands Holdings, Inc. ("Prestige Brands" or "Prestige") (NYSE: PBH), a leading marketer of branded consumer products, today announced that it has entered into a definitive agreement to acquire
Read more →PBHUnassociated Document Prestige Brands Holdings, Inc. Reports Fiscal First Quarter 2011 Results Irvington, NY
Brands Holdings, Inc. Reports Fiscal First Quarter 2011 Results NY, August 5, 2010-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the first quarter of fiscal 2011, which ended on June 30, income from continuing operations for the first quarter was $9.6 m
Read more →PBHPrestige Brands Holdings, Inc. Announces Appointment of Matthew Mannelly as Chief Executive Officer Also Announces Completion of 10% Staff Reduction Confirms September Quarter Revenues on Target Irvington, NY
Prestige Brands Holdings, Inc. Announces Appointment of Matthew Mannelly as Chief Executive Officer Also Announces Completion of 10% Staff Reduction Confirms September Quarter Revenues on Target Irvington, NY, September 3, 2009 - Prestige Brands Holdings, Inc. (NYSE-PBH) toda
Read more →Competitive Position
How PBH ranks across every disease it competes inCompetitive Position is a premium feature
See how PBH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial